华西证券（002926）此前发布研报称，公司三季度业绩符合预期，新签订单呈现加速趋势展望未来，考 虑到订单呈现快速增长，以及继续降本增效，及公司维持25年收入指引为12%~16%，判断未来业绩将 呈现边际改善趋势。 消息面上，康龙化成发布股份减持公告，合计持股14.17%的公司股东深圳市信中康成投资合伙企业(有 限合伙)(简称"信中康成")及其一致行动人深圳市信中龙成投资合伙企业(有限合伙)计划合计减持公司股 份不超过2667.29万股，占公司总股本的1.5%。 康龙化成（300759）(03759)现跌超5%，月内累计跌幅已超15%。截至发稿，跌5.41%，报22.04港元， 成交额1.29亿港元。 ...

Core Viewpoint - 康龙化成's stock has experienced a significant decline, dropping over 5% in a single day and more than 15% in the month, attributed to a share reduction announcement by major shareholders [1] Group 1: Stock Performance - 康龙化成's stock price is currently at 22.04 HKD, reflecting a decrease of 5.41% [1] - The total trading volume for the stock reached 1.29 billion HKD [1] Group 2: Shareholder Actions - Major shareholders, 深圳市信中康成投资合伙企业 and its acting party, plan to reduce their holdings by up to 26.67 million shares, which represents 1.5% of the total share capital [1] Group 3: Company Performance Outlook - 华西证券 reported that 康龙化成's Q3 performance met expectations, with new orders showing an accelerating trend [1] - The company maintains a revenue growth guidance of 12% to 16% over the next 25 years, indicating a potential for marginal improvement in future performance [1]

Group 1 - The core point of the article is that shareholders of Kanglong Chemical intend to reduce their holdings, leading to a decline in both A-shares and H-shares, which fell over 5% and reached new lows since mid-September [1] - The shareholders, Shenzhen Xincheng Kangcheng Investment Partnership and Shenzhen Xincheng Longcheng Investment Partnership, plan to reduce their holdings by up to 26.6729 million shares, accounting for no more than 1.5% of the company's total share capital [1] - The company has announced a total of four share reduction plans in the past three years, indicating a pattern of shareholder divestment [1]

Core Viewpoint - Kanglong Chemical experienced a decline of 5.02% on November 17, with a stock price of 29.90 yuan per share and a total market capitalization of 53.168 billion yuan [1] Company Overview - Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. was established on July 1, 2004, and went public on January 28, 2019. The company is located in Beijing Economic and Technological Development Zone [1] - The main business segments include laboratory services (60.43%), CMC (small molecule CDMO) services (21.58%), clinical research services (14.58%), and large molecule and cell & gene therapy services (3.28%) [1] Fund Holdings - The Xinda Australia Fund has a significant holding in Kanglong Chemical, with the Xinda Health China Mixed A Fund (003291) holding 959,400 shares, representing 5.41% of the fund's net value, making it the third-largest holding [2] - The fund has experienced a floating loss of approximately 1.5159 million yuan as of the latest data [2] Fund Manager Performance - The fund manager Li Junzhou has been in position for 165 days, with a total fund size of 634 million yuan and a best return of 11.17% during his tenure [3] - Yang Ke, another fund manager, has been in position for 5 years and 190 days, managing a total fund size of 1.324 billion yuan, with a best return of 43.77% during his tenure [3]

格隆汇11月17日丨根据联交所最新权益披露资料显示，2025年11月12日，康龙化成(03759.HK)获Norges Bank在场内以每股均价23.8072港元增持70.02万股，涉资约1667万港元。 | 芸植序线 | 大股東/董事/最高行政人員名 作出技擺的 買入 / 变出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的海關事件的日 相關法國股 債權證權益 | | --- | --- | --- | --- | --- | --- | | | | 原因 | 股份數目 | | ( 調金関上述*註 有投票權股期(日/月/ 份權益 | | | | | | | 份百分比 年) | | | | | | | ( 96 ) 日 1985 | | CS20251113E00453 Norges Bank | 700.200(L) | 1101(L) | | HKD 23.8072 | 18,270,424(L) 6.21(L)12/11/2025 | 增持后，Norges Bank最新持股数目为18,270,424股，持股比例由5.97%上升至6.21%。 ...

Core Viewpoint - The company 康龙化成 (300759.SZ) has received a share reduction plan notification from its major shareholders, indicating potential changes in ownership structure and market sentiment [1] Shareholder Reduction Plans - Shareholder 信中康成 holds 223,488,310 shares, approximately 12.57% of the total share capital, and plans to reduce its holdings by up to 8,890,977 shares, which is 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - Shareholder 信中龙成 holds 28,498,500 shares, about 1.60% of the total share capital, and intends to reduce its holdings by up to 17,781,955 shares, representing 1% of the total share capital, within the same three-month period [1]

Core Viewpoint - The company 康龙化成 (300759.SZ) has announced that its major shareholders, 深圳市信中康成投资合伙企业 and 深圳市信中龙成投资合伙企业, plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - 深圳市信中康成 plans to reduce its holdings by up to 8.891 million shares, which represents 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - 深圳市信中龙成 plans to reduce its holdings by up to 17.782 million shares, which represents 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - Kanglong Chemical (300759.SZ) announced that major shareholders plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - Shenzhen Xinchongkangcheng Investment Partnership (Limited Partnership) plans to reduce its holdings by up to 8.891 million shares, representing 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xinchonglongcheng Investment Partnership (Limited Partnership) intends to reduce its holdings by up to 17.782 million shares, accounting for 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - Kanglong Chemical (SZ 300759) announced a share reduction plan from major shareholders, which may impact the stock's performance and investor sentiment [1] Shareholder Reduction Plan - Shenzhen Xinchongkang Investment Partnership plans to reduce its holdings by up to approximately 8.89 million shares, accounting for 0.5% of the total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xinchonglong Investment Partnership plans to reduce its holdings by up to approximately 17.78 million shares, accounting for 1% of the total share capital, within the same timeframe [1] Financial Performance - For the year 2024, Kanglong Chemical's revenue composition is as follows: 99.95% from scientific research and technical services, and 0.05% from other businesses [1] - As of the report date, Kanglong Chemical's market capitalization stands at 56 billion yuan [1]

Core Viewpoint - The company announced that major shareholders plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - Shenzhen Xinchongkangcheng Investment Partnership (Limited Partnership) holds 223,488,310 shares, approximately 12.57% of the total share capital, and plans to reduce up to 8,890,977 shares, which is 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xindlongcheng Investment Partnership (Limited Partnership) holds 28,498,500 shares, approximately 1.60% of the total share capital, and plans to reduce up to 17,781,955 shares, which is 1% of the total share capital, within the same three-month period starting from December 8, 2025 [1]